menu search

LLY / Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today

Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
The trio was involved in a deal for gene-editing programs. The arrangement is potentially worth $600 million. Read More
Posted: Oct 31 2023, 19:09
Author Name: The Motley Fool
Views: 112488

LLY News  

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

By The Motley Fool
November 3, 2023

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo No more_horizontal

Expect Eli Lilly's momentum to continue, says Bank of America's Geoff Meacham

By CNBC Television
November 2, 2023

Expect Eli Lilly's momentum to continue, says Bank of America's Geoff Meacham

Geoff Meacham, Bank of America senior pharmaceutical analyst, joins 'The Exchange' to discuss Eli Lilly's performance, the demand outlook for weight l more_horizontal

Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics

By Zacks Investment Research
November 2, 2023

Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be wor more_horizontal

Novo Nordisk, Eli Lilly stocks see boost on obesity drugs

By Yahoo Finance
November 2, 2023

Novo Nordisk, Eli Lilly stocks see boost on obesity drugs

Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozem more_horizontal

Why Eli Lilly Stock Is Jumping Today

By The Motley Fool
November 2, 2023

Why Eli Lilly Stock Is Jumping Today

Lilly's Q3 revenue soared, but its earnings sank. However, the company's top- and bottom-line results handily beat Wall Street estimates. more_horizontal

Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook

By CNBC Television
November 2, 2023

Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically

By Barrons
November 2, 2023

Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically

Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9. more_horizontal

Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed

By Market Watch
November 2, 2023

Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed

Shares of Eli Lilly & Co. LLY, +0.10% dropped 1.8% in premarket trading Thursday, after the drug giant reported a surprise third-quarter profit but sl more_horizontal


Search within

Pages Search Results: